Literature DB >> 2899494

Antihypertensive treatment according to age, plasma renin and race.

F R Bühler1.   

Abstract

Recent large scale antihypertensive treatment trials emphasise the importance of blood pressure control in reducing both cerebrovascular accidents and myocardial infarction. Obviously therefore, the drug that best normalises blood pressure while producing the fewest adverse effects should be sought. On the basis of studies demonstrating cellular membrane and calcium homeostatic derangements and an age-dependent transition of overall cardiovascular regulation and peripheral vasoconstrictor forces during the course of essential hypertension, this review proposes an alternative treatment. Under this treatment scheme angiotensin converting enzyme inhibitors or beta-blockers should be used in younger patients and in those with high plasma renin activity, while calcium antagonists are used in place of diuretics in older low-renin or Black patients. Age-oriented 2-way drug selection enables a normalisation of blood pressure without untoward effects in about 80% of patients with essential hypertension and helps to optimise drug combinations in those patients who are difficult to treat.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2899494     DOI: 10.2165/00003495-198835050-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  62 in total

1.  Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects.

Authors: 
Journal:  Circulation       Date:  1972-05       Impact factor: 29.690

2.  Platelet function in hyperlipoproteinemia.

Authors:  A C Carvalho; R W Colman; R S Lees
Journal:  N Engl J Med       Date:  1974-02-21       Impact factor: 91.245

3.  Arterial hypertension elicited by prolonged intra-vertebral infusion of angiotensin II in conscious dog.

Authors:  C S Sweet; P J Kadowitz; M J Brody
Journal:  Am J Physiol       Date:  1971-12

4.  Relation between serum-free-fatty acids and arrhythmias and death after acute myocardial infarction.

Authors:  M F Oliver; V A Kurien; T W Greenwood
Journal:  Lancet       Date:  1968-04-06       Impact factor: 79.321

5.  Renin subgroups in essential hypertension. Further analysis of their pathophysiological and epidemiological characteristics.

Authors:  H R Brunner; J E Sealey; J H Laragh
Journal:  Circ Res       Date:  1973-05-05       Impact factor: 17.367

6.  Effect of age and high blood pressure on baroreflex sensitivity in man.

Authors:  B Gribbin; T G Pickering; P Sleight; R Peto
Journal:  Circ Res       Date:  1971-10       Impact factor: 17.367

7.  Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy.

Authors:  P Erne; P Bolli; E Bürgisser; F R Bühler
Journal:  N Engl J Med       Date:  1984-04-26       Impact factor: 91.245

8.  Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group.

Authors: 
Journal:  J Hypertens       Date:  1985-08       Impact factor: 4.844

9.  The place of the calcium antagonist verapamil in antihypertensive therapy.

Authors:  F R Bühler; U L Hulthén; W Kiowski; F B Müller; P Bolli
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

10.  Adrenaline induces vasoconstriction through post-junctional alpha 2 adrenoceptors and this response is enhanced in patients with essential hypertension.

Authors:  P Bolli; P Erne; B H Ji; L H Block; W Kiowski; F R Bühler
Journal:  J Hypertens Suppl       Date:  1984-12
View more
  13 in total

Review 1.  Are there benefits of antihypertensive therapy beyond blood pressure lowering?

Authors:  Joseph L Izzo
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

Review 2.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 3.  Essential hypertension in blacks: epidemiology, characteristics, and possible roles of racial differences in sodium, potassium, and calcium regulation.

Authors:  A Aviv; M Aladjem
Journal:  Cardiovasc Drugs Ther       Date:  1990-03       Impact factor: 3.727

Review 4.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 5.  Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.

Authors:  R W Piepho; K J Fendler
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 6.  Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  D McTavish; R A Young; S P Clissold
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

7.  Obesity as a determinant for response to antihypertensive treatment.

Authors:  R E Schmieder; C Gatzka; H Schächinger; H Schobel; H Rüddel
Journal:  BMJ       Date:  1993-08-28

8.  Transpulmonary pharmacokinetics of an ACE inhibitor (perindoprilat) in man.

Authors:  R J MacFadyen; K R Lees; J D Gemmill; W S Hillis; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

9.  The response to the first dose of an angiotensin converting enzyme inhibitor in uncomplicated hypertension--a placebo controlled study utilising ambulatory blood pressure recording.

Authors:  R J MacFadyen; A D Bainbridge; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 10.  Guidelines for treating hypertension in the elderly.

Authors:  J P Emeriau
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.